Comparison of efficacy of oral and injectable vitamin B12 in treatment of Vitamin B12 deficiency anemia in Children

AN OPEN LABEL RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF ORAL VS PARENTERAL VITAMIN B12 IN THE TREATMENT OF NUTRITIONAL MEGALOBLASTIC ANAEMIA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084524

Enrollment

114

Registered

2025-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D513- Other dietary vitamin B12 deficiency anemia

Interventions

Intervention1: VITAMIN B12: GROUP-A INJECTABLE Methycobalamin injection 1000mcg/dose intramuscular/intravenous on alternate days for 2 weeks followed by once weekly for 4 weeks (TOTAL DURATION- 6 week

Eligibility

Inclusion criteria

Inclusion criteria: mild to severe anemia b12 deficiency

Exclusion criteria

Exclusion criteria: severe anemia other co-morbidities like sickle cell disease, thalassemia, nephrotic syndrome, congenital heart diseases etc neurological manifestations, received blood transfusion in last 2 weeks had undergone gastric or duodenal surgeries in the past

Design outcomes

Primary

Measure	Time frame
Oral vitamin B12 treatment is as effective as Parenteral vitamin B12 treatment and can be set as the standard treatment protocol for megaloblastic anemiaTimepoint: 2 weeks, 6 weeks	—

Secondary

Measure	Time frame
Reticulocytosis, serum homocysteine & serum LDH as markers of vitamin b12 deficiencyTimepoint: 2 weeks, 6 weeks	—

Countries

India

Contacts

Public ContactViveka Mishra

Kalinga Institute of Medical Sciences, Bhubaneswar

palash.das@kims.ac.in9439035260

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026